NASDAQ · ASND
Ascendis Pharma A/S Ordinary Share financials
$228.07−0.86%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '19 Jun 30 | Q1 '19 Mar 31 | Q4 '18 Dec 31 | Q3 '18 Sep 30 | Q2 '18 Jun 30 | Q1 '18 Mar 31 | Q4 '17 Dec 31 | Q3 '17 Sep 30 | Q2 '17 Jun 30 | Q1 '17 Mar 31 | Q4 '16 Dec 31 | Q3 '16 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $157.0K | — | $1.5M | $40.8M | $9.0M | $8.2M | $4.3M | $27.2M | $3.5M | $2.9M | $8.5M | $2.4M |
| Gross profit | $157.0K | — | $1.5M | $40.8M | $9.0M | $8.2M | $4.3M | $27.2M | $3.5M | $2.9M | $8.5M | $2.4M |
| Gross margin | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$35.5M | -$33.8M | -$32.1M | $7.0M | -$28.9M | -$28.7M | -$29.7M | -$5.0M | -$23.8M | -$22.2M | -$14.7M | -$18.6M |
| Net income | -$41.1M | -$27.4M | -$36.2M | $5.2M | -$43.8M | -$21.1M | -$27.3M | -$878.0K | -$20.2M | -$21.8M | -$15.4M | -$18.5M |
| Net margin | −26170.1% | — | −2445.8% | 12.9% | −485.1% | −257.2% | −638.5% | −3.2% | −574.1% | −762.4% | −180.6% | −765.5% |
| Diluted EPS | $-0.07 | $-0.04 | $-0.06 | $0.01 | $-0.08 | $-0.04 | $-0.05 | — | $-0.04 | $-0.05 | $-0.04 | $-0.04 |
| EBITDA | -$33.5M | -$31.8M | -$32.1M | $8.9M | -$27.0M | -$26.9M | -$28.0M | -$3.5M | -$22.6M | -$21.2M | -$14.7M | -$17.8M |
| Operating cash flow | -$34.2M | -$36.2M | -$31.7M | $9.9M | -$35.4M | -$47.3M | -$21.4M | $13.5M | -$18.0M | -$28.4M | $2.4M | -$15.4M |
| Free cash flow | -$34.5M | -$37.1M | -$31.8M | $9.3M | -$36.6M | -$49.2M | -$23.2M | $11.9M | -$26.9M | -$40.7M | -$4.3M | -$17.3M |
| Diluted shares | 629.4M | 627.9M | 584.3M | 621.8M | 565.2M | 562.4M | 527.6M | 561.2M | 556.8M | 429.0M | 424.7M | 424.7M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $34.6M | $49.9M | $68.4M | $153.1M | $42.3M | $53.4M |
| Short-term investments | $98.8M | $118.2M | $136.8M | $84.7M | $86.7M | $108.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $239.5M | $270.4M | $276.7M | $309.6M | $211.3M | $247.1M |
| Total liabilities | $52.5M | $50.8M | $29.9M | $33.5M | $46.2M | $55.8M |
| Shareholders' equity | $187.0M | $219.7M | $246.9M | $276.2M | $165.1M | $191.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology